Localized Breast Cancer 2024 UPDATE

Today we are recapping exciting GU data presented at the 2026 ASCO Annual Meeting in bladder cancer, kidney cancer, and prostate cancer. 

This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial.The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) m ...  Show more

What does the cutting edge of radiation oncology look like for treating triple-negative breast cancer? Tune in to hear experts Drs Kevin Kalinsky and Reshma Jagsi discuss. Relevant disclosures can be found with the episode show notes on Medscape ( https://www.medscape.com/viewarti ...  Show more

Get ready for an insightful conversation in the second episode of Wellness Matters by American Hospital Dubai! We dive into how oncoplastic surgery, paired with cutting-edge seed technology, is transforming breast cancer treatment. This advancement is making tumor detection more ...  Show more

Patients with metastatic breast cancer whose tumors express low levels of HER2 are generally classified and treated as having HER2-negative disease.

However, Dr. Shanu Modi of the Memorial Sloan Kettering Cancer Center and a group of international collaborators explored ...

Did you know 1 in 8 women will get breast cancer in their lifetime? Join Lauren Bright Pacheco for a special episode from the 2024 ASCO Annual Meeting in Chicago, where she dives into the best collaborative approach to breast cancer diagnoses and care. Medical oncologist, Dr. Nan ...  Show more